/
Oncology
Liver Cancer
58
Pipeline Programs↗
64
Active Trials↗
42
Companies Involved↗
Liver Cancer is a moderately active landscape with 58 programs across 42 companies. The most active players are Zhejiang Raygene Pharmaceuticals Co., Ltd, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., CAS Lamvac Biotech Co., Ltd.. 10 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical17
Phase 19
Phase 222
Phase 310
Approved
No programs
Analysis
Modality Breakdown
65%
Small molecule
35 of 54 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 54 classified programs, each share of the total. Modality classified for 100% of 58 pipeline programs.
Analysis
Trial Status
285
clinical trials
Completed135 · 47%
Unknown status41 · 14%
Recruiting37 · 13%
Terminated34 · 12%
Not yet recruiting15 · 5%
Active, not recruiting12 · 4%
Other11 · 4%
Clinical Trials
Trial Activity
285 trials
Page 1 of 19
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)